Theradex Oncology
Leadership Team
Executive Leadership
Meg Valnoski
As President of Theradex for over 20 years, Ms. Valnoski has led Theradex operations including full-service trial support throughout the US, EU and Asia. Ms. Valnoski oversees regulatory affairs in the US collaborating with Theradex’s lead clinical scientists and EU regulatory experts to provide clients global development strategies for oncology drug products ranging from standard cytotoxic approaches to targeted combinations. She works closely with the diverse team of experts within Theradex to support the ongoing efforts to increase knowledge and the technical tools necessary to ensure the successful execution of your clinical trial. She facilitates communication between the clinical trial management staff and systems developers to ensure that clients have both the knowledge and the tools available to manage all phases of oncology trials across regions. Ms. Valnoski draws upon extensive experience interacting with clients and the regulatory authorities to help clients navigate through the changing regulatory environment driven by the evolution of personalized treatment approaches.
Ms. Valnoski works with the company senior leadership to support collaborations that provide clients with the combined benefit of long-term clinical development and project execution experience.
Barry Anderson, MD, PhD
At Theradex, Dr. Anderson acts as the medical and safety monitor for commercial phase I, II and III trials. He supervises the Clinical Operations teams and helps sponsors devise strategies for new agent evaluation and protocol development. Additionally, Dr. Anderson supervises Theradex’s Clinical Trial Monitoring Service team that reviews and audits early phase studies conducted by the National Cancer Institute. In the CTMS role, Dr. Anderson interacts with staff at the NCI Clinical Trials Monitoring Branch and Cancer Therapy Evaluation Program.
Dr. Anderson joined Theradex in 2007, after serving as a Senior Investigator at the Clinical Investigations Branch of the NCI Cancer Therapy Evaluation Program for eight years. While at NCI he worked closely with extramural NCI-supported investigators in the design, conduct and oversight of phase I, II and III cancer clinical trials conducted by the NCI Cooperative Groups. He served on numerous Data Safety Monitoring Boards for national cancer trials and was a leader in the development of the NCI-supported Pediatric Central IRB. Dr. Anderson was also an assistant professor and clinical attending in the Division of Pediatric Hematology, Oncology and Stem Cell Transplant at the Lombardi Cancer Center of Georgetown University for five years prior to joining the NCI. His experience with clinical patient care and the design and implementation of large, multi-institutional cancer treatment studies has provided Dr. Anderson with significant exposure to the scientific, regulatory and clinical aspects of contemporary cancer clinical trial conduct. Dr. Anderson received a Bachelor of Science in Biology from Lehigh University, a Ph.D. in Immunology from Duke University Medical Center and his medical degree from the University of Virginia. He trained in pediatric medicine at Northwestern University and completed a fellowship in Pediatric Hematology/Oncology and HIV research at the National Cancer Institute Pediatric Branch.
Hans Rosén
Since joining Theradex Oncology in 2019, Hans Rosén has been serving as the Managing Director for the company’s European operations. With a strong entrepreneurial background in the life sciences sector, he brings proven expertise in advancing cancer drug candidates, having successfully guided two from initial discovery through to first-in-human clinical trials. Before joining Theradex, Hans served as CEO for two publicly listed life science companies on the NASDAQ Stockholm stock exchange over a period of eight years.
Judy DeChamplain, MS, PMP
Since rejoining Theradex Oncology in 2016, Judy DeChamplain has direct line- management responsibilities for Clinical Operations, consisting of 7 key functional areas. Judy has 27 years of experience in Oncology Clinical Trials, obtained from both Theradex Oncology and Bristol-Myers Squibb. Her experience includes, but is not limited to; the design, conduct and execution of Oncology Phase I-IV trials, vendor management and project management. She has led teams in many successful regulatory submissions (US and worldwide), providing extensive planning, implementation and delivery of strategy, program plans and execution.
In addition to commercial operations support, Judy provides support to the Theradex Oncology NCI/CTMS contract, more specifically to the Data Safety Monitoring Board (DSMB), program of studies. Judy is a member of the Theradex Oncology Board of Directors.
Mike O’Gorman, CPA
Mike is a clinical industry veteran with experience as entrepreneur, CEO, CFO, EVP / CCO, and Board Chairman. After starting his career at KPMG, Mike went on to serve several financial roles within private industry and eventually became involved in executive operational and sales leadership roles. Mike’s approach towards serving customers is extremely consultative and he strives to ensure that customers receive the quality and timely service that they deserve.
Scientific Leadership
Barry Anderson, MD, PhD
Joachim Gullbo, MD, PhD
Dr. Gullbo was trained at Uppsala Academic Hospital in Sweden and is specialized in Medical Oncology and Clinical Pharmacology. During 2015-2017 (prior to joining Theradex Oncology) he served as the hospital’s Head of Oncology unit leading clinical recruitment and development as well as 35 full-time medical oncologists. Joachim also served as CMO, Advisor and founder of several biotech companies in Sweden.
Joachim holds a Doctor of Philosophy (PhD) degree in Clinical Pharmacology from Uppsala University, Sweden; Doctor of Medicine (MD), Uppsala University, Faculty of Medicine, Uppsala, Sweden; and a Master of Science (MSc) in Pharmacy, Uppsala University, Faculty of Pharmacy, Uppsala, Sweden.
As an academic researcher, Joachim has authored/co-authored over 85 peer-reviewed scientific publications, all publications available at https://www.ncbi.nlm.nih.gov/pubmed/?term=gullbo.
At Theradex, Dr. Gullbo works closely with sponsors for clinical drug development, including protocol design and medical monitoring and safety review for their clinical trials. His pharmacology background enables insight for sponsors as they contemplate their clinical strategy. He also plays a primary role in identifying key opinion leaders to ensure adequacy of the program’s scientific basis and endorsement on assumptions related to medical needs and clinical utility. Joachim’s experience includes Phase I and I/II (various solid tumors including glioma and ovarian cancer, AML/MDS, myeloma); Phase II: GEJ Cancer, Breast cancer, AML/MDS, Ovarian Cancer, glioblastoma; Phase III: MDS, multiple myeloma, and (as a co-investigator also breast cancer, colorectal cancer, glioma).
Jack Welch, MD, PhD
Jack brings his expertise for clinical trial development, execution and analysis to his role as Medical Monitor and Medical Safety Reviewer for our EU studies. In addition, he serves to harmonize our global experience and enrollment history for all of our studies to provide real-time metrics along with medical and scientific considerations.
Dr. Welch joined Theradex Oncology in 2019 after a decade at the US National Cancer Institute. At the NCI, Dr. Welch was head of the GI, Thoracic, and Rare Cancers portfolio within the Cancer Therapy Evaluation Program. He was also a senior investigator at the NCI Center for Global Health, where he promoted international clinical trial collaborations. Previously, he served as a senior clinical research physician at the European Organization for Research and Treatment of Cancer (EORTC).
Jack was trained in Experimental Therapeutics at Roswell Park Cancer Institute, with a PhD in pharmacology. His medical specialty is pediatric hematology-oncology, with fellowship training at Children’s Hospital of Philadelphia. Jack’s research background includes molecular and computational biology.
Richard S. Ungerleider, M.D.
Dr. Ungerleider provides expert advice in the design and conduct of phase I, phase 2, and large-scale pivotal oncology clinical trials, and participates in developing the research plans for pilot and laboratory-translational studies. He provides scientific leadership and medical guidance to clinical operations personnel at Theradex. Prior to joining Theradex in 2001, Dr. Ungerleider had been Chief of the Clinical Investigations Branch at the NCI for over a decade in which role he was responsible for the Clinical Trials Cooperative Group Program. His career in the U.S. Public Health Service spanned twenty-seven years, the last twenty-five of which were spent at the NCI. Dr. Ungerleider’s involvement in policy development to improve the conduct of oncology clinical trials provided him with extensive exposure to the scientific, regulatory, and industrial communities and familiarized him with the different interests of each.
Dr. Ungerleider received a Bachelor of Arts in Biology from the State University of New York at Binghamton’s Harpur College, and his medical degree from New York University. He trained in pediatric medicine at the Albert Einstein College of Medicine and at Stanford University, and underwent fellowship training in Pediatric Hematology/Oncology at Stanford and the National Cancer Institute Pediatric Branch. He is a Diplomate of the American Board of Pediatrics and the Sub-Board of Pediatric Hematology-Oncology.
Global Business Development
Jeanne Schow, MBA
Jeanne began her career in the pharma industry at Baxter Healthcare. She has experience with CROs as a Director, VP and SVP of Business Development building and leading CRO business development teams and optimizing solutions for potential customers to ensure seamless service delivery. Jeanne leads business development for the US and positions our services to exceed our prospective clients’ goals by bringing the appropriate operational, medical and regulatory experts together for each specific project.
Jeanne holds a B.S. in Industrial Technology from Cal Poly, San Luis Obispo, and an MBA from Pepperdine University in Malibu, California.
Philip van der Veen, PhD
Philip van der Veen joined Theradex Oncology in 2004 as Clinical Research Associate (CRA) and progressed to Sr. CRA and Clinical Project Manager. Currently he is the Business Development Director for prospective and existing clients with a focus on the UK and EU. In addition, he is responsible for the preparation of proposals and managing existing contracts. Philip graduated from the Vrije Universiteit Brussel in 1994 as Master in Physiotherapy and obtained his PhD in 2002. Before joining Theradex Oncology,
Philip worked part-time as Physiotherapist and as researcher at the Vrije Universiteit Brussel till 2002 and then full-time as Associate Professor at the same University until 2004.